Pfizer Inc. $PFE Shares Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.2% in the second quarter, Holdings Channel reports. The firm owned 309,137 shares of the biopharmaceutical company’s stock after acquiring an additional 25,954 shares during the period. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $7,444,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in PFE. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the 4th quarter valued at about $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $26,000. HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares during the period. Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC acquired a new position in Pfizer in the 4th quarter worth $31,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 0.8%

NYSE:PFE opened at $28.00 on Friday. The firm has a market capitalization of $159.59 billion, a PE ratio of 36.84 and a beta of 0.34. The stock has a 50 day moving average of $25.30 and a 200-day moving average of $26.25. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Finally, Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.28.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.